"Blood test for sepsis could save lives of thousands of children," reports the Mail Online.
Researchers in the US have developed a test for 5 proteins, which they say allows them to identify people with sepsis who have a high, medium or low risk of dying from the condition. They hope this will eventually help doctors identify the best treatments for individual patients.
Sepsis, sometimes called blood poisoning, is when the body's immune system over-reacts to an infection, causing inflammation and damage to the body's own tissues and organs. Anyone with an infection can get sepsis, although it is more common in babies and people over 75.
One of the challenges in treating sepsis is that symptoms can develop and worsen extremely quickly. So, a test that can confirm a diagnosis of sepsis before this happens should help reduce the risk of serious complications and, in some cases, deaths.
The test is still experimental. However, early experiments in mice suggest people at a high risk of dying from sepsis might benefit from higher doses of antibiotics than would normally be given.
Sepsis is a medical emergency. Find out more about the symptoms and what to do if you think someone may have sepsis.
The researchers who contributed to the study came from 16 institutions in the US, mainly children's hospitals. The research was led by Cincinnati Children's Hospital Medical Center. It was funded by grants from the US National Institutes of Health and Cincinnati Children's Hospital. The study was published in the peer-reviewed journal Science Translational Medicine.
The Mail Online did a good job of reporting a complicated study.
The researchers carried out a series of experiments, testing children with sepsis and then experimenting on mice to explore the results further. This is early-stage experimental research that may one day result in better treatment, but there is much more research to be done.
In earlier experiments, researchers had identified 5 proteins created by the body during sepsis, plus a measure of platelets (components in blood that make clots). They hoped the test, called Persevere II, would work to predict who was at highest risk of dying from sepsis.
They used the test on 461 children admitted to hospitals with sepsis, and divided them into 3 groups high, medium and low risk of death within 28 days. They then looked to see how accurately the test predicted what happened to the children. All children were treated as normal for sepsis in their admitting hospital.
The researchers then developed a mouse equivalent of the test, to see whether it would also predict survival in mice given sepsis in a laboratory experiment. They later investigated whether the higher-risk mice had more inflammation or more bacteria than low-risk mice. In 2 further experiments, they tested whether giving the high-risk mice steroids for inflammation, or higher-dose antibiotics to fight bacteria, changed their chances of survival. They also checked to see whether blocking 1 of the 5 proteins produced by the body and measured in the test affected the outcome.
Finally, researchers checked the results of the children with sepsis. They wanted to see if those classified as high risk by the Persevere II test were more likely to have had bacteria in their blood tests.
The researchers found the Persevere II test worked well to identify the risk level of children with sepsis. Almost all of the patients categorised as low risk survived, while just over half (55%) of those categorised as high risk survived. The test correctly identified as high risk 86% of those who did not survive (86% sensitivity) and correctly identified as low risk 69% of those who survived (69% specificity).
The test also worked well when predicting mice at high and low risk. Further experiments on mice showed high-risk mice had more signs of inflammation in the lungs and throughout the body as well as bigger colonies of bacteria from their infection.
Tests also showed that giving high-risk mice the anti-inflammatory drug dexamethasone or placebo made no difference to their survival, but they were more likely to survive if given high-dose antibiotics.
Mice given a drug to block 1 of the proteins used in the test were more likely to survive for 10 days, but the difference was small enough that the results could have come about by chance.
The researchers found that children who had been identified as high risk by the Persevere II test were more likely to have had bacteria cultured from their blood. While this is not a direct measure of the size of the bacteria colony, larger colony sizes are more likely to be able to be cultured after blood tests.
The researchers said: "On the basis of our findings, we suggest that Persevere II might identify a subgroup of children with septic shock [sepsis] who will benefit most from targeted therapeutic drug monitoring to ensure optimal dosing of antibiotics."
Because little is known about why sepsis happens after some infections, and how exactly it develops, it is hard to develop new treatments. Treatments have stayed the same for many years, and sepsis is a life-threatening condition.
This study is the first for many years to make some progress in our understanding of sepsis. It opens up possibilities for research into potential drugs that could be used in the future. This study also suggests ways in which the Persevere II test could be used to identify people at high risk of life-threatening sepsis, so they can be treated quickly and with the most appropriate dose of antibiotics.
However, this is very early-stage research. Just because a treatment works for mice does not mean it will work for humans. Translating results from a species to another, as the researchers do in this study, does not always work. Higher-dose antibiotics have not been tested for children identified as at high risk of life-threatening sepsis. Higher than usual doses could have damaging effects.
The Persevere II test is still being worked on, so is not yet generally available for doctors to use. In a media interview, a researcher said it is about 2 years away from being made available.
Sepsis can be hard to spot. There are lots of possible symptoms.
Find out more about spotting the signs of sepsis.
Analysis by BazianEdited by NHS Website
See more here:
New blood test could lead to better treatment for sepsis - NHS Website
- Breast Cancer Is Most Common Cancer In India, 1.38 Million Cases Diagnosed Annually. Know Estimated Incidence By 2030 - ABP Live - November 26th, 2023
- What Is Amyloidosis? All About The Rare Disease That Pervez Musharraf Suffered From - ABP Live - February 8th, 2023
- Autophagic death of neural stem cells mediates chronic stress-induced ... - November 7th, 2022
- Programmed cell death - Wikipedia - November 7th, 2022
- Hematopoietic Stem Cells | Hematopoiesis | Properties & Functions - September 4th, 2022
- Canadian Blood Services Stem Cells for Life - September 4th, 2022
- Devastation over death of schoolgirl, 11, who hoped she was beating cancer - Leicestershire Live - September 4th, 2022
- From optimized stem cell transplants to CAR T cell therapy: Advancing options for cancer, HIV and more - City of Hope - September 4th, 2022
- Scientists unlock the key to immortality in jellyfish - Syfy - September 4th, 2022
- Forge Biologics Reports Positive Clinical Data on Brain Development and Motor Function from the RESKUE Novel Phase 1/2 Gene Therapy Trial in Patients... - September 4th, 2022
- Menin Inhibitors Have Potential to Become the Next Class of Targeted Therapy in AML - Targeted Oncology - September 4th, 2022
- Wanted murder suspect John Belfield believed to still be in the UK as two more arrested over death of Thomas Campbell - The Manc - September 4th, 2022
- Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study | Blood Cancer Journal... - July 8th, 2022
- Can minds persist when they are cut off from the world? - Livescience.com - July 8th, 2022
- Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population - Cancer Network - July 8th, 2022
- Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in... - July 8th, 2022
- How abortion ruling could affect IVF and embryonic research - The Almanac Online - July 8th, 2022
- This Morning viewers 'in tears' after boy meets donor who saved his life - Devon Live - July 8th, 2022
- Alpena detective: 'Good people out there' | News, Sports, Jobs - Alpena News - July 8th, 2022
- 'I miss my best friend': Five-year-old runs 10k to honour girl who died from rare brain tumour - Teesside Live - July 8th, 2022
- Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by... - July 8th, 2022
- Novartis AG, AstraZeneca Plc, and Pfizer Inc Among Leading Companies in the Thyroid Cancer Pipeline Products Market | Globaldata Plc - Yahoo Finance - July 8th, 2022
- A New Strategy Could Turn the Tide in Stem Cell GVHD - Medical Device and Diagnostics Industry - January 17th, 2022
- Vertex type 1 diabetes vs stem cell therapy - The Boar - January 17th, 2022
- Two-Year OS Doubles for Patients With Philadelphia-Positive Relapsed ALL After HSCT - AJMC.com Managed Markets Network - January 17th, 2022
- Nowakowski Considers CD19 Therapy in Transplant-Ineligible DLBCL - Targeted Oncology - January 17th, 2022
- Psaki demolishes Doocy with stats as he tries to claim covid now an illness of the vaccinated - newsconcerns - January 17th, 2022
- Doctors and Researchers Probe How COVID-19 Attacks the Heart - The Scientist - January 17th, 2022
- Who does donated blood that's direly needed help? - WTOP - January 17th, 2022
- Places Where Omicron is Most Contagious Eat This Not That - Eat This, Not That - January 17th, 2022
- UHN and U of T receive $24-million federal grant for transplant research - News@UofT - January 17th, 2022
- Glycyrrhizic acid ameliorates submandibular gland oxidative stress, autophagy and vascular dysfunction in rat model of type 1 diabetes | Scientific... - January 17th, 2022
- Stem cells in cancer therapy: opportunities and challenges - January 1st, 2022
- Life After Brain Death: Is the Body Still 'Alive'? | Live ... - January 1st, 2022
- Autologous Adult Stem Cells in the Treatment of Stroke | SCCAA - Dove Medical Press - January 1st, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 1st, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 1st, 2022
- Upregulated expression of actin-like 6A is a risk factor | CMAR - Dove Medical Press - January 1st, 2022
- COVID-19 Takes a Toll on People with Blood Cancers and Disorders - Cancer Health Treatment News - January 1st, 2022
- Mental health disorders and heart diseases - Rising Kashmir - January 1st, 2022
- Research breakthrough could mean better treatment for patients with most deadly form of brain tumor - EurekAlert - October 26th, 2021
- European Commission Approves Merck's KEYTRUDA (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable... - October 26th, 2021
- European Commission Selects Humanigen's Lenzilumab as One of the 10 Most Promising Treatments for COVID-19 - Galveston County Daily News - October 26th, 2021
- Everything You Need To Know About COVID Booster Shots - Colorado Times Recorder - October 26th, 2021
- Stem cells and their role in lung transplant rejection - Michigan Medicine - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- Will humans ever be immortal? - Livescience.com - October 5th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Faster healing of wounds can decrease pain and suffering and save lives - ABC 12 News - October 5th, 2021
- U.S. FDA Approves Kite's Tecartus as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia - Business... - October 5th, 2021
- Skeletons' broken clavicles tell a centuries-old tale of humans and horses - Massive Science - October 5th, 2021
- Environmental Factor - August 2021: Extramural Papers of the Month - Environmental Factor Newsletter - August 4th, 2021
- Role of traumatic brain injury in the development of glioma | JIR - Dove Medical Press - August 4th, 2021
- Targeted Therapeutics Market: Increase in Incidence of Cancer to Drive Global Market - BioSpace - August 4th, 2021
- Accumulation of Regulatory T Cells in Triple Negative Breast Cancer Ca | CMAR - Dove Medical Press - August 4th, 2021
- Novel CAR-T Cell Therapy Produces Early and Deep Responses in Certain Patients with Multiple Myeloma - Curetoday.com - June 7th, 2021
- Autophagy suppresses the formation of hepatocyte-derived cancer-initiating ductular progenitor cells in the liver - Science Advances - June 7th, 2021
- Cancer research: New advances and innovations - Medical News Today - June 7th, 2021
- Fulvestrant Alone Found to be Superior to Venetoclax/Fulvestrant Combo in ER+/HER2- Breast Cancer - Targeted Oncology - June 7th, 2021
- Merck's KEYTRUDA Given After Surgery Reduced the Risk of Disease Recurrence or Death by 32% Versus Placebo as Adjuvant Therapy in Patients With Renal... - June 7th, 2021
- Stem cell study illuminates the cause of an inherited heart disorder | Penn Today - Penn Today - February 14th, 2021
- The race to treat a rare, fatal syndrome may help others with common disorders like diabetes - Science Magazine - February 14th, 2021
- Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with... - February 14th, 2021
- The Very First Signs of an Immune Response Have Been Filmed in a Developing Embryo - ScienceAlert - February 14th, 2021
- Arlo's Army needs stem cell donor as mum begs for help to save three-year-old's life - Glasgow Live - February 14th, 2021
- Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV (enfortumab vedotin-ejfv) in Patients with Previously... - February 14th, 2021
- [Full text] Successful Use of Nivolumab in a Patient with Head and Neck Cancer Aft | OTT - Dove Medical Press - February 14th, 2021
- The drug treatments offering the best hope of a way out of the Covid crisis - Telegraph.co.uk - February 14th, 2021
- In the war against Covid, an arsenal of drugs is on the way - Telegraph.co.uk - February 14th, 2021
- Kat Wests husband, Jeff West, sentenced to 16 years in wifes death - AL.com - February 9th, 2021
- Harnessing the Potential of Cell and Gene Therapy - OncLive - February 9th, 2021
- I Survived Cancer, and Then I Needed to Remember How to Live - The Atlantic - February 9th, 2021
- [Full text] Higher Red Blood Cell Distribution Width is a Poor Prognostic Factor f | CMAR - Dove Medical Press - February 9th, 2021
- West Belfast woman to be remembered in special TV documentary - Belfast Live - January 29th, 2021
- UTV documentary tells of young Belfast woman's lasting legacy to promote stem cell donation - The Irish News - January 29th, 2021
- L-MIND Trial Results Show CD19 Antibody Is Reasonable in R/R DLBCL - Targeted Oncology - January 29th, 2021
- Vertex Announces FDA Clearance of Investigational New Drug (IND) Application for VX-880, a Novel Cell Therapy for the Treatment of Type 1 Diabetes... - January 29th, 2021
- If I Have Cancer, Dementia or MS, Should I Get the Covid Vaccine? - Kaiser Health News - January 29th, 2021
- Experimental taphonomy of organelles and the fossil record of early eukaryote evolution - Science Advances - January 29th, 2021